This study aimed to demonstrate equivalent efficacy and safety between salbutamol delivered via the HFA134a pMDI (Hydrofluoroalkane134a pressurised Metered Dose Inhaler) and theTurbuhalert dry powder inhaler in asthmatic children.This was a randomised, double-blind, double-dummy, placebo-controlled, crossover studyin10 asthmatic children aged 6^15 years who demonstrated at least 10% reversibility of FEV 1 after inhaling 400 mg of salbutamol. On 5 single study days subjects received either placebo or cumulative doses of100, 200,400 and 800 mg of salbutamol at 30 minuteintervals.Both deviceswere placebo on one studyday, while each device was active ontwo studydays.FEV 1 was measured before and 20 minutes after each dose.Heart rate was measured before spirometry.Mean FEV 1 and heart rate ateachtime point and the area under the dose response time curve (AUC) were analysed using ANOVA.FEV 1 increased similarly after cumulative doses of salbutamol on each ofthe study days, irrespective of device.Meantreatmentdifference in AUCwas 0.01L.min (95%CI^0.05 to 0.08L).Heartdid notdiffer at anydose.Itis concludedthat salbutamol delivery from a HFA pMDI and Turbuhalertis equivalenton a microgram basisin asthmatic children for efficacy and safety.
INTRODUCTION
The pressurised Metered-dose inhaler (pMDI) is the most commonly used metered-dose inhaler. Traditionally formulated with CFCs, it is now available with a new CFC-free propellant, hydro£uoroalkane 134a (HFA). Some patients (including the elderly and very young) can have di⁄culties in co-ordinating the use of pMDIs, but this can be largely overcome by using a spacer or using a breath-activated dry powder inhaler (DPI) instead (1) .
Some DPIs (such as theTurbuhalert (TH)FTurbuhalert is a trademark of AstraZeneca Pharmaceuticals.) have been claimed to give better drug deposition in the lungs than the pMDI, resulting in higher e⁄cacy (2, 3) . Data in adults have shown equivalent e⁄cacy and safety between salbutamol delivered via the HFA pMDI or the TH (4), however, and the aim of the current study was to assess this in paediatrics.
METHODS
Ten children aged 6^15 years (mean 12 years) with a history of asthma,X10% reversibility from baseline in FEV 1 after inhaling 400 mg of salbutamol and demonstrated ability to use both devices, were enrolled into this randomised, double-blind, double-dummy, placebo-controlled, crossover study. Prior to enrolment the subjects' legal guardians gave written informed consent for their participation and the subjects gave their assent.
On 5 single study days, subjects received either placebo or cumulative doses of100, 200, 400 and 800 mg of salbutamol at 30 min intervals. On each dosing occasion, they inhaled from both devices (according to the standard instructions supplied by the manufacturers) and received either an HFA pMDI (100 mg/actuation) and TH placebo, aTH (100 mg/actuation) and HFA pMDI placebo, or placebo from both devices. Both devices were placebo on 1 study day, while each device was active on 2 study days, the data from which were then combined for analysis to minimise variability. Dosing started at the same time on each study day (7 1h ) and the days were at least 46 h apart to avoid any carry-over e¡ects. FEV 1 was measured using a turbine spirometer before and 20 min after each dose for three times on each occasion, and the highest value noted. The spirometer was checked daily using a 3 l precision syringe. Heart rate was measured before spirometry over 1min using a stethoscope. Before dosing, subjects had to have withheld from taking short-acting b 2 -agonists for 6 h and long-acting b 2 -agonists for 12 h, and have a baseline FEV 1 within 715% of their screening value.
The study was designed to show equivalence between the HFA pMDI and TH, de¢ned as the 95% con¢dence intervals (95% CI) for the mean treatment di¡erence being within 70.25 l for FEV 1 and 78 beats/min (bpm) for heart rate. Analysis of the mean FEV 1 and heart rate at each time point and the area under the dose response time curve (AUC) was performed using analysis of covariance, allowing for e¡ects due to subjects, periods, predosing values and treatments.
RESULTS

FEV 1
FEV 1 increased similarly after cumulative doses of salbutamol on each of the study days, irrespective of delivery device (Fig. 1) . The adjusted mean treatment di¡erence between the HFA pMDI and TH was well within the equivalence criteria at each dose, e.g. after 100 mg it was 0.02 l (95% CI À0.05 to 0.09 l), and after 800 mg was 0.04l (95% CI À0.05 to 0.12l).The mean treatment di¡erence in the AUC was 0.01l.min (95% CI À0.05 to 0.08 l). Both devices were signi¢cantly better than placebo for both the increase in FEV 1 and the AUC (Po0.001).
Heart rate
The adjusted mean treatment di¡erence between the HFA pMDI and TH at each dose was well within the pre-de¢ned equivalence limits. The largest di¡erence (after 200 mg of salbutamol) was À2.4 bpm (95% CI À5.6 to 0.9), and at the maximum dose (800 mg) it was only À1.8 bpm (95% CI À 5.2 to 1.7). There was no di¡erence in AUC observed between devices (mean treatment difference of À1.0 bpm min) [95% CI À3.0 to1.1]), and no signi¢cant di¡erence between either device and placebo.
DISCUSSION
This study demonstrates clinical equivalence between the pMDI and TH in children with asthma in terms of the e¡ect of salbutamol on lung function (FEV 1 ) or the systemic parameter of heart rate. This is in accordance with adult data (4) and with other studies which have demonstrated equivalent e⁄cacy between the TH and other DPIs such as the Diskus (5).
It has been claimed that only half the dose of drug is required from aTH when compared to either a pMDI or Diskhaler due to improved lung deposition (2, 3, 6, 7) . In these studies, the drugs were not compared at microgram equivalent doses, however, and they are contradicted by in vitro studies which show a more accurate dose of salbutamol and a higher ¢ne particle mass from the pMDI than the TH (8) . Furthermore, the e¡ective-ness of a bronchodilator delivered from aTH is more dependent upon inspiratory £ow than from a pMDI (9), except where inhalation from the pMDI is too fast.Taking all this together, therefore, we do not believe that there are any di¡erences in the dose required to achieve similar relief between these two devices.
In conclusion, salbutamol delivery from a HFA pMDI and TH is equivalent on a microgram basis in children with asthma for both e⁄cacy and safety.
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